Progenics Pharmaceuticals

YTD

ALL

Why Robinhood?

You can watch PGNX and buy or sell other stocks, ETFs, and their options commission-free!

About PGNX

Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology.

CEO

David W. Mims, CPA

CEODavid W. Mims, CPA

Employees

—

Employees—

Headquarters

New York, New York

HeadquartersNew York, New York

Founded

1986

Founded1986

Employees

—

Employees—

PGNX Key Statistics

Market cap

355.05M

Market cap355.05M

Price-Earnings ratio

-5.30

Price-Earnings ratio-5.30

Dividend yield

—

Dividend yield—

Average volume

4.50M

Average volume4.50M

High today

—

High today—

Low today

—

Low today—

Open price

—

Open price—

Volume

0.00

Volume0.00

52 Week high

$6.37

52 Week high$6.37

52 Week low

$1.89

52 Week low$1.89

People also own

Based on the portfolios of people who own PGNX. This list is generated using Robinhood data, and it’s not a recommendation.